Rare Disease Intelligence
Strategic coverage of orphan drug development, regulatory reform and competitive landscape dynamics.
Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026
April 16, 2026
A comprehensive review of nearly 20 newly approved rare disease drugs worldwide in March 2026, covering hematology, oncology, metabolic disorders, and gene therapy.
2026 Global Innovative Drug R&D and Regulatory Dynamics: ADC and Gene Therapies Lead a New Era
April 10, 2026
In 2026, global innovative drug R&D continues to accelerate, with Antibody-Drug Conjugates (ADCs) and gene therapies taking center stage. This article deeply analyzes the latest approval dynamics from the FDA and NMPA, and explores how these cutting-edge technologies are reshaping the landscape of oncology and rare disease treatments.
Global Pharmaceutical Innovation and Regulatory Dynamics in 2026: Breakthroughs in Oncology and Rare Diseases
April 09, 2026
Global Access to Thalassemia Gene Therapy in 2026: USA vs Europe vs China
April 08, 2026
Where can patients access thalassemia gene therapy? Compare the United States, Europe, and China in terms of cost, availability, and clinical access.
CRISPR Gene Therapy Enters the Clinical Era: Casgevy Approval Marks the Dawn of Gene Editing Treatments
April 03, 2026
The approval of Casgevy, the world’s first CRISPR-based therapy, marks a historic milestone in medicine, transitioning gene editing from lab research to life-changing clinical treatment.
FGFR Inhibitors: Emerging Targeted Therapies for Rare Skeletal Disorders
March 23, 2026
New Breakthroughs in Clinical Research on Paroxysmal Nocturnal Hemoglobinuria (PNH) from a Global Perspective
March 18, 2026
The Rise of China’s Rare Disease Drugs: From Follower to Emerging Global Leader
February 27, 2026
China’s rare disease drug industry is transitioning from generics-based participation to innovation-driven global competitiveness, supported by regulatory reform, biotechnology advancement, cost efficiency, and industrial integration.
Why Humanity Continues to Invest in Orphan Drug Research — Despite Only 5% of Rare Diseases Being Treatable
February 27, 2026
Only 5% of rare diseases have approved treatments. Yet global investment in orphan drug research continues to grow. This article examines the scientific, ethical, and systemic drivers behind sustained rare disease innovation.